Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $360,023 - $550,624
29,828 Added 106.44%
57,850 $852 Million
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $506,637 - $657,115
28,022 New
28,022 $513 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.